Roy S Herbst

Roy S Herbst

Yale University - New Haven / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 846655
person_outline Roy S Herbst's MOST POPULAR ARTICLES
1-) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial The Lancet 387 (10027), 1540-1550, 2016
2-) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 (7528), 563-567, 2014
3-) The biology and management of non-small cell lung cancer Nature 553 (7689), 446-454, 2018
4-) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial Jama 290 (16), 2149-2158, 2003
5-) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non … Journal of Clinical Oncology 22 (11), 2184-2191, 2004